Japanese pharma in the UK

About this episode

This episode explores the influence of Japanese pharmaceutical companies in the UK, featuring insights from Jackie Davis of Astellas Pharma.

In this episode, we’ll take a look at the role of Japanese pharmaceutical groups in the UK, with Jackie Davis, general manager at Astellas Pharma. Tokyo-headquartered Astellas (TYO: 4503) has developed a strong portfolio in urology, oncology and immunology, most recently with US FDA approval for Vyloy (zolbetuximab), a key addition to its cancer treatments. It’s one of many Japanese companies with a strong presence in the UK, represented nationally by the Japanese Pharmaceutical Group, of w...

People in this episode

Host: Simon Wentworth

Guest: Jackie Davis

Topics covered

• Japanese pharmaceutical industry
• Astellas Pharma
• cancer treatments
• UK market
• pharmaceutical groups

Keywords

• Japanese pharma
• Astellas
• oncology
• urology
• immunology
• Vyloy
• UK pharmaceutical market

Mentioned in this episode

Organizations: Astellas Pharma, Japanese Pharmaceutical Group

Products: Vyloy, zolbetuximab

Places: UK, Tokyo

More episodes of The Pharma Letter Podcast

• BenevolentAI CEO on the future of AI-led medicine · May 6, 2026 · 30 min
• ConcertAI CEO Eron Kelly on Big Tech's role in biotech · March 13, 2026 · 18 min
• How blood cancer treatment is evolving in the Middle East · December 8, 2025 · 22 min
• Nouscom bets on dual vaccine strategy to outsmart cancer · July 25, 2025 · 20 min
• Is this a revolution in Alzheimer's? · June 12, 2025 · 21 min
• Why Boehringer and GSK are betting on Ochre · May 23, 2025 · 19 min